GlassScriptPhysician profile
Taylor Danielle Prince
NPI 1669061461
$14,105.54
in general payments reported to CMS, 2019-2025
32 companies · $3,517 in 2025
The $3,517 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,428 · 2022: $2,463 · 2023: $3,264 · 2024: $3,432 · 2025: $3,517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,687 · Education: $526.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,687.47 |
| Education | $526.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,880.82 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,489.46 | 2021-2025 | |
| Genzyme Corporation | $1,051.57 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $868.36 | 2021-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $794.35 | 2021-2025 | Sotyktu |
| Lilly USA, LLC | $736.53 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Leo Pharma INC. | $672.08 | 2021-2025 | Adbry, Anzupgo |
| Dermavant Sciences, INC. | $666.15 | 2022-2024 | Vtama |
| Janssen Biotech, INC. | $579.17 | 2021-2025 | Tremfya |
| Ucb, INC. | $537.91 | 2021-2025 | Bimzelx |
| Pfizer INC. | $478.10 | 2021-2025 | |
| Incyte Corporation | $471.71 | 2021-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $270.55 | 2021-2025 | |
| Biofrontera INC. | $257.02 | 2021-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Amgen INC. | $236.65 | 2021-2025 | Otezla, Otezla |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $210.29 | 2023-2025 | Nemluvio, Aklief, Oracea |
| Arcutis Biotherapeutics, INC. | $176.73 | 2023-2025 | Zoryve |
| Organon LLC | $153.84 | 2025 | Vtama |
| Sanofi-Aventis U.S. LLC | $89.95 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.16 | 2023-2024 | Spevigo |
| Paratek Pharmaceuticals, INC. | $69.54 | 2024-2025 | Nuzyra |
| Mayne Pharma Commercial LLC | $63.96 | 2025 | |
| Genentech USA, INC. | $57.60 | 2022-2024 | Erivedge |
| Fresenius Kabi USA, LLC | $36.43 | 2023-2024 | Idacio |
| Verrica Pharmaceuticals INC. | $35.89 | 2023-2025 | Ycanth |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $32.46 | 2022-2024 | Cabtreo |
| Botanix Sb INC | $19.82 | 2025 | Sofdra |
| Epi Health, LLC | $19.30 | 2022 | |
| Mimedx Group, INC. | $18.68 | 2025 | |
| Journey Medical Corporation | $17.11 | 2023 | |
| Almirall LLC | $16.68 | 2023 | Klisyri |
| Helsinn Therapeutics (U.S.), INC. | $12.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Prince listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.